301 related articles for article (PubMed ID: 32872487)
1. Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.
Moerman-Herzog A; Mehdi SJ; Wong HK
Cells; 2020 Aug; 9(9):. PubMed ID: 32872487
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.
Moerman-Herzog AM; Acheampong DA; Brooks AG; Blair SM; Hsu PC; Wong HK
Oncotarget; 2019 Aug; 10(49):5052-5069. PubMed ID: 31489115
[TBL] [Abstract][Full Text] [Related]
3. Sézary Syndrome, recent biomarkers and new drugs.
Cristofoletti C; Narducci MG; Russo G
Chin Clin Oncol; 2019 Feb; 8(1):2. PubMed ID: 30525758
[TBL] [Abstract][Full Text] [Related]
4. Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling.
Mehdi SJ; Moerman-Herzog AM; Wong HK
J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723945
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome.
Fraser-Andrews EA; Russell-Jones R; Woolford AJ; Wolstencroft RA; Dean AJ; Whittaker SJ
Cancer; 2001 Oct; 92(7):1745-52. PubMed ID: 11745245
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
7. Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
[TBL] [Abstract][Full Text] [Related]
8. Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study.
Mangold AR; Thompson AK; Davis MD; Saulite I; Cozzio A; Guenova E; Hodak E; Amitay-Laish I; Pujol RM; Pittelkow MR; Gniadecki R
J Am Acad Dermatol; 2017 Oct; 77(4):719-727. PubMed ID: 28709694
[TBL] [Abstract][Full Text] [Related]
9. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
[TBL] [Abstract][Full Text] [Related]
10. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
12. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
[TBL] [Abstract][Full Text] [Related]
13. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE).
Wood GS; Tung RM; Haeffner AC; Crooks CF; Liao S; Orozco R; Veelken H; Kadin ME; Koh H; Heald P
J Invest Dermatol; 1994 Jul; 103(1):34-41. PubMed ID: 8027579
[TBL] [Abstract][Full Text] [Related]
14. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.
Saulite I; Hoetzenecker W; Weidinger S; Cozzio A; Guenova E; Wehkamp U
Biomed Res Int; 2016; 2016():9717530. PubMed ID: 27294147
[TBL] [Abstract][Full Text] [Related]
15. Novel approach to gene expression profiling in Sézary syndrome.
Pomerantz RG; Mirvish ED; Erdos G; Falo LD; Geskin LJ
Br J Dermatol; 2010 Nov; 163(5):1090-4. PubMed ID: 20698843
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous histopathology of Sézary syndrome: a study of 41 cases with a proven circulating T-cell clone.
Trotter MJ; Whittaker SJ; Orchard GE; Smith NP
J Cutan Pathol; 1997 May; 24(5):286-91. PubMed ID: 9194581
[TBL] [Abstract][Full Text] [Related]
17. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
18. CD3
Carpentier C; Schandené L; Dewispelaere L; Heimann P; Cogan E; Roufosse F
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2426-2439.e7. PubMed ID: 33545400
[TBL] [Abstract][Full Text] [Related]
19. Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment.
Borcherding N; Severson KJ; Henderson N; Ortolan LS; Rosenthal AC; Bellizzi AM; Liu V; Link BK; Mangold AR; Jabbari A
Blood Adv; 2023 Feb; 7(3):321-335. PubMed ID: 35390145
[TBL] [Abstract][Full Text] [Related]
20. [Epidermotropic T cell lymphomas as models for tumor progression].
Bagot M; Bensussan A
Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
